Ikena Oncology Inc (NAS:IKNA)
$ 1.735 -0.115 (-6.22%) Market Cap: 83.73 Mil Enterprise Value: -47.05 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 30/100

Ikena Oncology Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 11, 2021 / 08:30PM GMT
Release Date Price: $16.26 (-2.81%)
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

Hi and welcome to the afternoon session of the 2021 Credit Suisse Healthcare Conference. I'm Judah Frommer. I cover biotech here at CS. With us for this session, we have Ikena. We're thrilled to have a good chunk of the team here, Mark, Sergio and Doug. I'll just let the audience know that if you do have questions for the team, you can certainly e-mail those to me at [email protected]. But with that intro, maybe we'll all hop right into our Q&A list, which is reasonably lengthy.

Questions & Answers

Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

So Mark, I thought we could start with a brief history lesson on Ikena. How from a high level your approach across targeted oncology and tumor microenvironment is somewhat differentiated versus peers.

Mark Manfredi
Ikena Oncology, Inc. - President. CEO & Director

Sure. Thanks for having us,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot